Authors

Vali A. Papadimitrakopoulou, MD, The University of Texas MD Anderson Cancer Center

Latest:

Dr Velcheti on the FDA Approval of Repotrectinib in ROS1+ Metastatic NSCLC

Vamsidhar Velcheti, MD, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

Vamsidhar Velcheti, MD, FACP

Latest:

Dr. Velcheti on the Importance of Real-World Data in NSCLC

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

Van K. Morris, MD

Latest:

Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Vanessa Caceres

Latest:

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Vassiliki A. Papadimitrakopoulou, MD

Latest:

Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

Vassiliki A. Papadimitrakopoulou, MD, University of Texas MD Anderson Cancer Center

Vassiliki Liana Tsikitis, MD

Latest:

Colorectal Cancer: A Review

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Vassiliki Papadimitrakopoulou, MD

Latest:

Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.

Vassiliki Papadimitrakopoulou, MD, MD Anderson Cancer Center

Veda Giri, MD

Latest:

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Veda N. Giri, MD

Latest:

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Vernon K. Sondak, MD

Latest:

Dr. Sondak on Ipilimumab in Melanoma

Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.

Vernon K. Sondak, MD, Moffitt Cancer Center

Veronique Dieras, MD

Latest:

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Veronique Leblond, MD

Latest:

Dr. Leblond Discusses Treatment After Relapse in CLL

Veronique Leblond, MD, head of the Department of Hematology, Pitié Salpêtrière Hospital, Paris, France, discusses the treatment of patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial treatment.

Vicki Albrecht, PhD

Latest:

Build Referrals and Strengthen Revenues

Multiple resources are available to help community oncologists maintain success by increasing awareness of their practice, providing the most innovative treatments to their patients, and preparing for the future of oncology care.

Vicki Hyman

Latest:

Esserman Helps Push Breast Cancer Prevention Beyond Routine Screenings

Laura J. Esserman, MD, MBA, a 2018 Giants of Cancer Care® award winner in the Cancer Diagnostics category led the way in designing the I-SPY clinical trials, a groundbreaking effort to match patients with breast cancer to potential therapies based on molecular drivers of disease. She also has advocated for a greater understanding of the biological drivers of breast cancer, rather than relying on mass screening programs, to better analyze early disease.

Vicki Keedy, MD

Latest:

Dr. Keedy Discusses Imaging Biomarkers in Osteosarcoma

Vicki Keedy, MD, assistant professor of medicine, clinical director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses a trial looking at quantitative imaging biomarkers of treatment response in osteosarcoma.

Vicky Makker, MD

Latest:

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.